

## Facile one-pot four-component synthesis of 3,4-dihydro-2-pyridone derivatives: novel urease inhibitor scaffold

Arash Modarres Hakimi<sup>1</sup>, Negar Lashgari<sup>2</sup>, Shabnam Mahernia<sup>1</sup>, Ghodsi Mohammadi Ziarani<sup>3</sup>, and Massoud Amanlou<sup>1,\*</sup>

<sup>1</sup>Drug Design & Development Research Centre and Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, I.R. Iran.

<sup>2</sup>School of Chemistry, College of Science, University of Tehran, Tehran, I.R. Iran.

<sup>3</sup>Department of Chemistry, Alzahra University, Tehran, I.R. Iran.

### Abstract

In the current study, a series of 3,4-dihydro-2-pyridone derivatives were synthesized in a one-pot four-component reaction of Meldrum's acid, benzaldehyde derivatives, methyl acetoacetate, and ammonium acetate. SiO<sub>2</sub>-Pr-SO<sub>3</sub>H was used as an efficient catalyst for the synthesis of the target compounds under solvent-free conditions. The most probable mechanism for this reaction has been discussed. The advantages of this methodology are high product yields, being environmentally benign, short reaction times, and easy handling. Eight 2-pyridinone derivatives were evaluated for their inhibitory activities against Jack bean urease. Molecular docking study of the synthesized compounds was also evaluated. All compounds showed good activities against urease and among them, 4-(4-nitrophenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (**5a**) showed the most potent activity (IC<sub>50</sub> = 29.12 μM), more potent than hydroxyurea as the reference drug (IC<sub>50</sub> = 100.0 μM). Also, the results from docking studies were in good agreement with those obtained with *in vitro* assay. According to the docking studies methionine (Met) 637 and nitro phenyl ring cause n-π interaction between lone pair of sulfur atom and π aromatic ring. Moreover, hydrophobic interactions existed between compound **5a** and alanine (ALA) 636, ALA 440, and isoleucine 411. The results indicated that the inhibitory activities increased with the increase of electron withdrawing ability of the groups despite a less important role of lipophilicity in increasing the inhibitory activity.

**Keywords:** Multicomponent reaction; Urease inhibitory activity; 3,4-Dihydro-2-pyridone derivatives; SiO<sub>2</sub>-Pr-SO<sub>3</sub>H

### INTRODUCTION

In 1926, crystallized urease from Jack bean urease (EC 3.5.1.5) by James B. Sumner was the first nickel-containing enzyme. The life cycle, pathogenesis of *Helicobacter pylori* (*H. pylori*) is very appertaining to the presence of nickel in its environment (1).

Urease catalyzes hydrolysis of urea to ammonia and carbon dioxide which neutralizes gastric acid and increases pH in stomach. Urease plays an important role in the nitrogen metabolism, acid resistance, and virulence of *H. pylori* and represented up to 10% of total protein content of the bacteria (2-4).

*H. pylori* have been colonized in the gastric epithelium of humans for at least 58,000 years.

*H. pylori* infection leads to chronic gastritis that most people have no symptoms but is the main risk factor for peptic ulcer, duodenal ulcer, mucosa-associated lymphoid tissue (MALT) lymphoma, and adenocarcinoma (5-7). Existing therapeutic regimens have lost some efficacy due to high level of antibiotic resistance to *H. pylori* and poor patient compliance.

Urease activity control through the use of inhibitors can overcome these shortcomings (8-10). So far, several urease inhibitors are presented; Fig. 1 shows the chemical structure of some of them.


#### Access this article online



Website: <http://rps.mui.ac.ir>

DOI: 10.4103/1735-5362.213980

\*Corresponding author: M. Amanlou  
Tel: +98-2166959067, Fax: +98-2164121111  
Email: amanlou@tums.ac.ir



**Fig. 1.** Chemical structures of urease inhibitors

Multicomponent reactions (MCR) have become popular in organic, medicinal, and combinatorial chemistry because they address both diversity and complexity in organic synthesis. MCR is defined as a process in which three or more different components are combined to yield ideally a single product. Such procedures reduce time and save both energy and starting materials (11-13).

The current literature reveals that 1,4-dihydropyridine derivatives (1,4-DHP) exhibit interesting biological activities such as anti-inflammatory (14), antitubercular (15), antiatherosclerotic (16), and anticancer activities (17). 1,4-DHP derivatives are also a class of heterocyclic compounds well-known as  $\text{Ca}^{2+}$  channel blockers (18). 2-Pyridones are structurally very similar to 1,4-DHP. Compounds with such structures are found to possess various biological and pharmacological properties (19-21). Although several different methods have been reported for the preparation of 2-pyridone derivatives, development of new synthetic methods for efficient synthesis of this class of compounds is still an interesting challenge.

Recently, the emphasis on green chemical principles introduced some significant

advances in organic synthesis (22,23). In this regard, heterogeneous catalysts have found considerable interest in organic reactions, since these catalysts can be recovered and reused several times after the reaction without significant loss of reactivity. Reactions with these catalysts are generally clean and selective and give high yields of products.

In continuation of our research on the multicomponent synthesis of heterocyclic compounds of biological importance (24-27), herein we wish to report a green and efficient procedure for the synthesis of 3,4-dihydro-2-pyridone derivatives in the presence of  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$  as a heterogeneous acid catalyst under solvent-free conditions with potential urease inhibitory activity.

## MATERIALS AND METHODS

### Materials

All commercially available chemicals were purchased from Merck Company (Germany) and used without further purification. IR spectra were recorded from KBr disk using a FT-IR Bruker Tensor 27 instrument (USA). Melting points measured by using the capillary tube method with an electro thermal

9200 apparatus (Bibby Scientific Limited, Staffordshire, UK) are uncorrected. The  $^1\text{H}$  NMR (250 MHz) and  $^{13}\text{C}$  NMR (125 MHz) were run on a Bruker DPX (USA) at 250 MHz in  $\text{CDCl}_3$  and 125 MHz in  $\text{D}_2\text{O}$  using tetramethylsilane as internal standard. GC-Mass analysis was performed on a GC-Mass model: 5973 network mass selective detector, GC 6890 Agilent Technologies (USA).

#### Preparation of catalyst ( $\text{SiO}_2\text{-Pr-SO}_3\text{H}$ )

$\text{SiO}_2\text{-Pr-SO}_3\text{H}$  was prepared according to our previous report (28) and was used as a solid acid catalyst in the following reaction.

#### General procedure for the synthesis of 2-pyridone derivatives 5a-5h

The  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$  (0.02 g) was activated in vacuum at 100 °C and after cooling the catalyst to room temperature, Meldrum's acid **1** (0.43 g, 3 mmol), methyl acetoacetate **2** (0.32 mL, 3 mmol), aromatic aldehyde **3** (3 mmol), and ammonium acetate **4** (0.38 g, 5 mmol) were added. The mixture was heated under solvent-free condition at 140 °C for the time reported in Table 1. The progress of reaction was monitored by thin layer chromatography. The generated solid product was dissolved in hot ethanol, filtered for removing the catalyst, and then the filtrate was cooled to afford the pure product.

#### Spectral data

##### 4-(4-Nitrophenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (**5a**)

Mp 210-212 °C; IR (KBr): 3375, 1697, 1638, 1517, 1349  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (500 MHz,

$\text{D}_2\text{O}$ ):  $\delta$  8.14-8.16 ( $^2\text{H}$ , m, ArH), 7.56 ( $^1\text{H}$ , s, NH), 7.25-7.35 ( $^2\text{H}$ , m, ArH), 4.35 ( $^1\text{H}$ , d,  $J = 8.0$  Hz), 3.66 ( $^3\text{H}$ , s,  $\text{OCH}_3$ ), 3.01 ( $^1\text{H}$ , dd,  $J = 16.5$  Hz, 8.0 Hz), 2.67 ( $^1\text{H}$ , dd,  $J = 16.5$  Hz, 8.0 Hz), 2.45 ( $^3\text{H}$ , s,  $\text{CH}_3$ ) ppm;  $^{13}\text{C}$  NMR (125 MHz,  $\text{D}_2\text{O}$ ):  $\delta_{\text{C}}$  19.3, 37.5, 37.9, 51.6, 105.8, 124.1, 127.6, 136.5, 140.2, 143.3, 147.2, 149.4, 166.7, 169.7; MS (EI,  $m/z$ ): 290 ( $\text{M}^+$ ).

##### 4-(3-Nitrophenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (**5b**)

Mp 204-206 °C; IR (KBr): 3351, 1704, 1648, 1528, 1348  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (250 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.03-8.35 ( $^3\text{H}$ , m, ArH, NH), 7.24-7.73 ( $^2\text{H}$ , m, ArH), 4.34 ( $^1\text{H}$ , dd,  $J = 8.0$  Hz, 1.5 Hz), 3.66 ( $^3\text{H}$ , s,  $\text{OCH}_3$ ), 3.01 ( $^1\text{H}$ , dd,  $J = 16.4$  Hz, 8.0 Hz), 2.66 ( $^1\text{H}$ , dd,  $J = 16.4$  Hz, 1.5 Hz), 2.45 ( $^3\text{H}$ , s,  $\text{CH}_3$ ) ppm; MS (EI,  $m/z$ ): 290 ( $\text{M}^+$ ).

##### 4-(4-Methoxyphenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (**5c**)

Mp 188-190 °C; IR (KBr): 3217, 1691, 1631, 1249, 1085  $\text{cm}^{-1}$ ; MS (EI,  $m/z$ ): 275 ( $\text{M}^+$ ).

##### 4-Phenyl-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (**5d**)

Mp 193-194 °C; IR (KBr): 3218, 1696, 1638, 1282, 1086  $\text{cm}^{-1}$ ; MS (EI,  $m/z$ ): 245 ( $\text{M}^+$ ).

##### 4-(4-Chlorophenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (**5e**)

Mp 195-198 °C; IR (KBr): 3218, 1694, 1633, 1281, 1082  $\text{cm}^{-1}$ ; MS (EI,  $m/z$ ): 279 ( $\text{M}^+$ ).

**Table 1.** Synthesis of 3,4-dihydro-2-pyridones **5a-5h** under optimized conditions.

Entry	Aldehyde	Product	Time (min)	Yield (%) <sup>a</sup>	M.p. <sup>b</sup> (°C)	M.p. <sup>c</sup>
1	4- $\text{NO}_2\text{C}_6\text{H}_4$	<b>5a</b>	45	89	210 - 212	210 - 211 (34)
2	3- $\text{NO}_2\text{C}_6\text{H}_4$	<b>5b</b>	40	90	204 - 206	205 - 206 (35)
3	4- $\text{OCH}_3\text{C}_6\text{H}_4$	<b>5c</b>	60	78	188 - 190	187 - 188 (33)
4	Ph	<b>5d</b>	32	93	193 - 194	197 - 198 (33)
5	4- $\text{ClC}_6\text{H}_4$	<b>5e</b>	25	93	195 - 198	198 - 200 (34)
6	2,4-( $\text{OCH}_3$ ) $_2\text{C}_6\text{H}_3$	<b>5f</b>	30	89	140 - 141	136 - 139 (35)
7	2,4- $\text{Cl}_2\text{C}_6\text{H}_3$	<b>5g</b>	25	90	203 - 206	204 - 206 (35)
8	2- $\text{OCH}_3\text{C}_6\text{H}_4$	<b>5h</b>	35	88	202 - 205	206 - 208 (35)

(a), Isolated yields; (b), melting point; (c), as reported in the literature.

**4-(2,4-Dimethoxyphenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (5f)**

Mp 140-141 °C; IR (KBr): 3225, 1694, 1611, 1260, 1036 cm<sup>-1</sup>; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): δ 8.20 (<sup>1</sup>H, br s, NH), 7.26 (<sup>1</sup>H, s, ArH), 7.04 (<sup>1</sup>H, d, *J* = 9.25 Hz, ArH), 6.86 (<sup>1</sup>H, d, *J* = 5.25 Hz, ArH), 4.63 (<sup>1</sup>H, dd, *J* = 8.3 Hz, 1.9 Hz), 3.75 (<sup>3</sup>H, s, OCH<sub>3</sub>), 3.70 (<sup>3</sup>H, s, OCH<sub>3</sub>), 3.46 (<sup>3</sup>H, s, OCH<sub>3</sub>), 2.80 (<sup>1</sup>H, dd, *J* = 16.5 Hz, 8.3 Hz), 2.42 (<sup>1</sup>H, dd, *J* = 16.5 Hz, 1.9 Hz), 1.50 (<sup>3</sup>H, s, CH<sub>3</sub>) ppm; MS (EI, *m/z*): 305 (M<sup>+</sup>).

**4-(2,4-Dichlorophenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (5g)**

Mp 203-206 °C; IR (KBr): 3229, 1705, 1642, 1591, 800 cm<sup>-1</sup>; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): δ 8.79 (<sup>1</sup>H, br s, NH), 7.40 (<sup>1</sup>H, s, ArH), 7.14 (<sup>1</sup>H, d, *J* = 7.5 Hz, ArH), 6.96 (<sup>1</sup>H, d, *J* = 8.25 Hz, ArH), 4.64 (<sup>1</sup>H, dd, *J* = 8.3 Hz, 1.9 Hz), 3.60 (<sup>3</sup>H, s, OCH<sub>3</sub>), 2.94 (<sup>1</sup>H, dd, *J* = 16.5 Hz, 8.3 Hz), 2.78 (<sup>1</sup>H, dd, *J* = 16.5 Hz, 1.9 Hz), 2.45 (<sup>3</sup>H, s, CH<sub>3</sub>) ppm; MS (EI, *m/z*): 313 (M<sup>+</sup>).

**4-(2-Methoxyphenyl)-5-methoxycarbonyl-6-methyl-3,4-dihydropyridone (5h)**

Mp 202-205 °C; IR (KBr): 3240, 1699, 1634, 1245, 1051 cm<sup>-1</sup>; <sup>1</sup>H NMR (250 MHz, CDCl<sub>3</sub>): δ 8.15 (<sup>1</sup>H, br s, NH), 7.26 (<sup>1</sup>H, d, *J* = 10 Hz, ArH), 7.19 (<sup>1</sup>H, d, *J* = 7.75 Hz, ArH), 6.79-6.96 (<sup>2</sup>H, m, ArH), 4.57 (<sup>1</sup>H, dd, *J* = 8.3 Hz, 1.9 Hz), 3.83 (<sup>3</sup>H, s, OCH<sub>3</sub>), 3.60 (<sup>3</sup>H, s, OCH<sub>3</sub>), 2.87 (<sup>1</sup>H, dd, *J* = 16.5 Hz, 8.3 Hz), 2.77 (<sup>1</sup>H, dd, *J* = 16.5 Hz, 1.9 Hz), 2.42 (<sup>3</sup>H, s, CH<sub>3</sub>) ppm; MS (EI, *m/z*): 275 (M<sup>+</sup>).

**Urease inhibitory assay**

Urease (EC 3.5.1.5) from Jack beans and sodium nitroprusside were purchased from Sigma (USA). Ultra-pure water, (HPLC grade, Duksan, Korea) was used throughout the experiments. Measuring the release of ammonia by a modification of the Berthelot reaction determined the urease inhibitory activity of the synthesized compound (29-30). The reaction mixture consisted of urea (850 μL, 25 mM), 15 μL of urease enzyme solution (2 mg/mL) and 135 μL of the test compounds of various concentrations in 100 mM sodium phosphate buffer (pH 7.4). Mixture was pre-incubated for 30 minutes in water bath at 37 °C. After pre-incubation, 100 μL of mixture

were mixed with 500 μL of phenol reagent (contained 2.5 mg of sodium nitroprusside and 0.5 g phenol in 50 mL of distilled water) and 500 μL of alkaline reagent containing 820 μL of sodium hypochlorite 5% and 250 mg sodium hydroxide in 50 mL of distilled water. After further 30 min incubation at 37 °C, absorbance was measured at 625 nm.

**Data processing**

The inhibition percentage (I (%)) was calculated by the following equation:

$$I (\%) = 100 - ((A_{\text{INH}}/A_{\text{B}}) \times 100)$$

where, A<sub>INH</sub> is the absorbance of the tested sample and A<sub>B</sub> is the absorbance of the solvent in the presence of enzyme. The IC<sub>50</sub> values were calculated using GraphPad Prism 6 software. All experiments were performed in triplicate and hydroxyurea was used as the standard compound which is already confirmed to have significant inhibitory characteristics for urease.

**Molecular docking**

Eight compounds have sketched by Marvin sketch applet (Marvin package, Chemaxon Company, Hungary). Afterward polar hydrogens and rotatable bonds was added with AutoDockTools 1.5.6 (ADT). The crystal structure of *H. pylori* urease enzyme with resolution of 2.05 Å was downloaded from the protein data bank (3LA4, <http://www.pdb.org>) and was used for docking studies (31,32). In the present study, the metal ions and non-standard protein residues (KCX and CME) were contained within the binding site specification but before initiating the docking simulations, all ligands and all water molecules were removed from urease structure file with ADT. A grid map was used consisted of 70 × 70 × 70 Å points around the active site and calculated by AutoGrid 4.2. The center of the grid was set to the mean coordinates of the two Ni<sup>2+</sup> ions in the α chain of the urease enzyme. Docking with a maximum number of 25 × 10<sup>6</sup> energy evaluations were performed by AutoDock 4.2. The other docking parameters were set to default values. Once clustering analysis was performed, selection of the conformation based on the most favorable binding energy was done.


## RESULTS

In the present work, we explored the catalytic activity of  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$  toward the clean one-pot synthesis of pyridone derivatives (Scheme 1). At first, the effect of different solvents on the reaction times and yields of the product **5d** was examined. For this purpose, the model reaction of Meldrum's acid **1**, methyl acetoacetate **2**, benzaldehyde **3**, and ammonium acetate **4** was investigated in various solvents such as  $\text{H}_2\text{O}$ , MeCN, EtOH, EtOH/ $\text{H}_2\text{O}$  (1:1), and solvent-free system (Table 2). It was found that solvent-free medium was the most effective condition in terms of reaction time (32 min) and yield of compound **5d** (93%). To determine the optimum temperature, we investigated the model reaction at room temperature, 50 °C, 140 °C, and the best result was obtained at 140 °C. Then, in regard to library construction, we extended our study with different substituted aldehydes under solvent-free condition at 140 °C in the presence of a catalytic amount of  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$ . The results are summarized in Table 1. A series of pyridine derivatives were successfully synthesized in high yields and appropriate times. It was reported that this reaction could be observed when the aliphatic aldehydes were used as starting materials (33).

The structures of some products were characterized by spectral analysis and melting points were compared with values reported in the literature (Table 1).

This reaction may occur via a condensation, addition, cyclization, and elimination mechanism (Scheme 2). After protonation of carbonyl groups of Meldrum's acid and benzaldehyde derivatives by the solid acid catalyst, a Knoevenagel condensation occurs between Meldrum's acid and the corresponding benzaldehyde to afford the intermediate **6**. Then, intermediate **6** undergoes a Michael-type addition with enamino compound **7** (resulting from the reaction of ammonia and methyl acetoacetate). Finally, intramolecular cyclodehydration in intermediate **8** provides the desired product **5**.

The NMR experiment also confirmed the formation of the pyridone rings. The  $^1\text{H}$  NMR spectrum of compound **5b** shows the two protons on C-3 as a part of an ABX system which was confirmed by a doublet of doublet at  $\delta = 4.34$  corresponding to the proton on C-4 due to the splitting by coupling with the protons on C-3 ( $J = 8.0$  Hz and  $J = 1.5$  Hz). Due to the greater acidity of Meldrum's acid ( $\text{pK}_a = 9.97$ ) in comparison with methyl acetoacetate ( $\text{pK}_a = 11.0$ ), we do not obtain 1,4-dihydropyridines.




**Scheme 1.** Four-component synthesis of 3,4-dihydro-2-pyridone derivatives in the presence of  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$ .

**Table 2.** Effect of different solvents for the yield of compound **5d**.

Entry	Solvent	Temperature (°C)	Time (min)	Yield (%) <sup>a</sup>
1	$\text{H}_2\text{O}$	Reflux	200	85
2	EtOH/ $\text{H}_2\text{O}$ (1:1)	Reflux	230	90
3	MeCN	Reflux	140	75
4	EtOH	Reflux	150	72
5	-	140 °C	32	93

(a) Isolated yields.



**Scheme 2.** The possible mechanism for the preparation of compounds **5a-5h** in the presence of  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$ .

**Table 3.** Comparison of  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$  and various catalysts in the synthesis of **5d**.

Entry	Catalyst	Solvent	Condition	Time (min)	Yield (%)	Year
1	-	EtOH	Reflux	360	26	1990 (36)
2	-	AcOH	Reflux	600	65	1996 (37)
3	-	-	Microwave	15	86	2003 (35)
4	polyphosphoric acid (2-3 drops)	-	Microwave	5	88	2008 (33)
5	-	AcOH	Ultrasound	12	85	2011 (34)
6	SBA-Pr-SO <sub>3</sub> H (0.02 g)	-	Heating (140 °C)	40	90	2013 (38)
7	$\text{SiO}_2\text{-Pr-SO}_3\text{H}$ (0.02 g)	-	Heating (140 °C)	32	93	This work

Table 3 illustrates a comparison of the effectiveness of various catalysts used in the synthesis of 2-pyridone derivatives. The results illustrate that  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$  provided an efficient route to access these compounds. Because of green chemistry viewpoint, the reusability of the catalyst was investigated under optimized conditions for the synthesis of the model compound **5d**.

The process of recycling was completed four times and no significant decrease in activity was observed. The yields for the four runs were found to be 93, 87, 81, and 76%, respectively.

Eight 2-pyridinone derivatives were evaluated for their inhibitory activities against

Jack bean urease which is similar to *H. pylori* urease in its structure. All of these compounds showed good activity against urease and four of test compounds (**5a**, **5b**, **5e**, and **5g**) showed potent urease inhibitory activities, in comparison to hydroxyurea as a standard inhibitor with  $\text{IC}_{50}$  equal to 100  $\mu\text{M}$  (Table 4).

Compound **5a** showed the most potent inhibitory activity against urease ( $\text{IC}_{50} = 29.12 \mu\text{M}$ ). Compounds containing nitro group and chlorine showed greater inhibitory. This result indicated that the inhibitory activities increased with the increase of electron withdrawing ability of the groups despite a less important role of lipophilicity in increasing the inhibitory activity.

**Table 4.** Inhibitory concentration, binding energy and two-dimensional interaction of 3,4-dihydro-2-pyridone derivatives with urease active site.

Product	Structure	IC <sub>50</sub> (μM)	Docking energy (kcal/mol)	KI (μM)
5a		29.12	-6.5	17.17
5b		48.84	-5.97	42.3
5c		119.9	-4.21	455.41
5d		131.3	-4.64	395.83

**Table 4.** (Continued)

Product	Structure	IC <sub>50</sub> (μM)	Docking energy (kcal/mol)	KI (μM)
5e		84.08	-4.35	293.22
5f		102.5	-4.13	419.27
5g		81.99	-4.65	348.37
5h		158.5	-4.18	445.04



## DISCUSSIONS

To investigate the binding effects between compound **5a** and the *H. pylori* urease the molecular docking study was performed. In the binding model nitro group coordinates with both nickel ions and also asparagine (ASP) 637 and KCX 490. Met 637, CME 592, and histidine (HIS) 492 formed hydrogen bonds and also oxygen of glutamine (GLN) 635 formed a hydrogen bond with pyridine NH.

According to docking studies Met 637 and nitrophenol ring causes  $\pi$ - $\pi$  interaction between sulfur atom of amino acid and the ring. Moreover, hydrophobic interactions existed between compound **5a** and ALA 636, ALA 440, and isoleucine (ILE) 411.

Shifting of nitro group from para to meta position in compound **5b** caused less hydrogen bonds and therefore less inhibitory activity ( $IC_{50} = 48.84 \mu\text{M}$ ) compare to compound **5a**. This is probably because of different molecule orientation in active site.

In compound **5e**, which nitro group substituted with Cl result in just two hydrogen bonds with MET 637 and CME 592. Cl and ALA 636 showed hydrophobic interactions and also an  $n$ - $\pi$  interaction between ring and MET 637 ( $IC_{50} = 84.08 \mu\text{M}$ ). Adding another Cl to ortho position of the ring in compound **5g** slightly improved inhibitory activity due to increase in hydrophobic interactions between two Cl and MET 588, ALA 440, leucine (LEU) 589, Met 637, and CME 592 ( $IC_{50} = 81.99 \mu\text{M}$ ).

Although compound **5d** did not coordinate with nickel ions formed four hydrogen bonds with ALA 636, MET 637, CME 592, and arginine (ARG) 439 ( $IC_{50} = 131.3 \mu\text{M}$ ). Methoxy group added to para position of the ring in compound **5c** ( $IC_{50} = 119.9 \mu\text{M}$ ) and two methoxy group to para and ortho positions of ring in compound **5f** ( $IC_{50} = 102.5 \mu\text{M}$ ) resulted in increasing hydrophobic interactions between the compounds and amino acids of the *H. pylori* urease.

The confirmation of compound **5h** in the active site of urease led to less inhibition activity ( $IC_{50} = 158.5 \mu\text{M}$ ) in comparison to other compounds.

## CONCLUSIONS

In conclusion, we have demonstrated that  $\text{SiO}_2\text{-Pr-SO}_3\text{H}$  is an efficient catalyst for the synthesis of 3,4-dihydro-2-pyridone derivatives under solvent-free conditions. High yields of the products, short reaction times, and simplicity of the system make it an improved protocol in comparison with existing methods. We evaluated inhibitory activity of synthesized compounds through jack bean urease and all of them showed inhibitory activity against urease. Compound **5a** showed good inhibition compared to hydroxyurea.

## ACKNOWLEDGEMENTS

We gratefully acknowledge financial support of the Research Council of Alzahra University and University of Tehran and Tehran University of Medical Sciences.

## REFERENCES

1. Palizban A, Saghaie L. Synthesis and evaluation of the complex-forming ability of hydroxypyranones and hydroxypyridinones with Ni (II) as possible inhibitors for urease enzyme in *Helicobacter pylori*. Res Pharm Sci. 2016;11(4):332-342.
2. Mobley HLT, Hausinger RP. Microbial ureases: significance, regulation, and molecular characterization. Microbiol Rev. 1989;53(1):85-108.
3. Kusters JG, van Vliet AHM, Kuipers EJ. Pathogenesis of *Helicobacter pylori* infection. Clin Microbiol Rev. 2006;19(3):449-490.
4. Bauerfeind P, Garner R, Dunn BE, Mobley HL. Synthesis and activity of *Helicobacter pylori* urease and catalase at low pH. Gut. 1997;40(1):25-30.
5. Wroblewski LE, Peek RM Jr, Wilson KT. *Helicobacter pylori* and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23(4):713-739.
6. Salama NR, Hartung ML, Muller A. Life in the human stomach: persistence strategies of the bacterial pathogen *Helicobacter pylori*. Nat Rev Microbiol. 2013;11:385-399.
7. Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol. 2006;208(2):233-248.
8. Khan KM, Wadood A, Ali M, Zia-Ullah, Ul-Haq Z, Lodhi MA, et al. Identification of potent urease inhibitors via ligand- and structure-based virtual screening and *in vitro* assays. J Mol Graph Model. 2010;28(8):792-798.
9. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of *Helicobacter pylori* infection-- the maastricht IV/ florence consensus report. Gut. 2012;61(5):646-664.

10. Barbosa LCA, Oliveira FM, Valente VMM, Demuner AJ, Maltha CRA, Oliveros-Bastidas AJ. Structure–activity relationship of pyridin-2(1H)-ones derivatives as urease inhibitors. *J Pharm Res.* 2012;5(12):5326-5333.
11. Mohammadi Ziarani G, Moradi R, Lashgari N. Synthesis of spiro-fused heterocyclic scaffolds through multicomponent reactions involving isatin. *Arkivoc.* 2016;i:1-81.
12. Dömling A, Wang W, Wang K. Chemistry and biology of multicomponent reactions. *Chem Rev.* 2012;112(6):3083-3135.
13. de Graaff C, Ruijter E, Orru RV. Recent developments in asymmetric multicomponent reactions. *Chem Soc Rev.* 2012;41(10):3969-4009.
14. Tale RH, Rodge AH, Hatnapure GD, Keche AP, Patil KM, Pawar RP. The synthesis, anti-inflammatory, and anti-microbial activity evaluation of new series of 4-(3-arylsureido)phenyl-1,4-dihydropyridine urea derivatives. *Med Chem Res.* 2013;22:1450-1455.
15. Desai NC, Trivedi AR, Somani HC, Bhatt KA. Design, synthesis, and biological evaluation of 1,4-dihydropyridine derivatives as potent antitubercular agents. *Chem Biol Drug Des.* 2015;86(3):370-377.
16. Carosati E, Ioan P, Micucci M, Broccatelli F, Cruciani G, Zhorov BS, et al. 1,4-dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (Part 2): action in other targets and antitargets. *Curr Med Chem.* 2012;19(25):4306-4323.
17. Radadiya A, Khedkar V, Bavishi A, Vala H, Thakrar S, Bhavsar D, et al. Synthesis and 3D-QSAR study of 1,4-dihydropyridine derivatives as MDR cancer reverters. *Eur J Med Chem.* 2014;74:375-387.
18. Kang S, Cooper G, Dunne SF, Luan CH, James Surmeier D, Silverman RB. Antagonism of L-type Ca<sup>2+</sup> channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics. *Bioorg Med Chem.* 2013;21(14):4365-4373.
19. Collins I, Moyes C, Davey WB, Rowley M, Bromidge FA, Quirk K, et al. 3-Heteroaryl-2-pyridones: Benzodiazepine site ligands with functional selectivity for  $\alpha 2/\alpha 3$ -subtypes of human gabaa receptor-ion channels. *J Med Chem.* 2002;45(9):1887-1900.
20. Desai NC, Dodiya AM, Shihory NR. A search of novel antimicrobial based on benzimidazole and 2-pyridone heterocycles. *Med Chem Res.* 2012;21(9):2579-2586.
21. Desai NC, Rajpara KM, Joshi VV. Synthesis of pyrazole encompassing 2-pyridone derivatives as antibacterial agents. *Bioorg Med Chem Lett.* 2013;23(9):2714-2717.
22. Jessop PG. Searching for green solvents. *Green Chem.* 2011;13:1391-1398.
23. Sheldon RA. Fundamentals of green chemistry: efficiency in reaction design. *Chem Soc Rev.* 2012;41:1437-1451.
24. Mohammadi Ziarani G, Faramarzi S, Asadi S, Badiei A, Bazl R, Amanlou M. Three-component synthesis of pyrano[2,3-d]-pyrimidine dione derivatives facilitated by sulfonic acid nanoporous silica (SBA-Pr-SO<sub>3</sub>H) and their docking and urease inhibitory activity. *Daru.* 2013;21(1):3. doi: 10.1186/2008-2231-21-3.
25. Lashgari N, Mohammadi Ziarani G, Badiei A, Zarezadeh-Mehrzi M. Application of sulfonic acid functionalized sba-15 as a new nanoporous acid catalyst in the green one-pot synthesis of spirooxindole-4h-pyrans. *J Heterocycl Chem.* 2014;51(6):1628-1633.
26. Mohammadi Ziarani G, Hosseini Mohtasham N, Lashgari N, Badiei A. Efficient one-pot synthesis of 2H-indazolo[2,1-b]phthalazinetrione derivatives with amino-functionalized nanoporous silica (SBA-Pr-NH<sub>2</sub>) as catalyst. *Res Chem Intermed.* 2015;41:7581-7591.
27. Mohammadi Ziarani G, Moradi R, Badiei A, Lashgari N, Moradi B, Abolhasani Soorki A. Efficient green synthesis of 3,3-di(indolyl)indolin-2-ones using sulfonic acid functionalized nanoporous SBA-Pr-SO<sub>3</sub>H and study of their antimicrobial properties. *J Taibah Univ Sci.* 2015;9(4):555-563.
28. Mohammadi Ziarani G, Badiei A, Lashgari N, Pourjafar T, Farahani Z. Silica-based sulfonic acid (SiO<sub>2</sub>-Pr-SO<sub>3</sub>H): an efficient catalyst in the green one-pot synthesis of 3,4-dihydropyrimidinones/thiones. *Bulg Chem Commun.* 2015;46(42):719-723.
29. Nabati F, Mojab F, Habibi-Rezaei M, Bagherzadeh K, Amanlou M, Yousefi B. Large scale screening of commonly used Iranian traditional medicinal plants against urease activity. *Daru.* 2012;20:72-81.
30. Vosoghi M, Farzipour S, Saeedi M, Shareh NB, Mahdavi M, Mahernia Sh, et al. Synthesis of novel 5-arylidene (thio)barbituric acid and evaluation of their urease inhibitory activity. *J Iran Chem Soc.* 2015;12(8):1487-1491.
31. Azizian H, Nabati F, Sharifi A, Siavoshi F, Mahdavi M, Amanlou M. Large-scale virtual screening for the identification of new helicobacter pylori urease inhibitor scaffolds. *J Mol Model.* 2012;18(7):2917–2927.
32. Ahari-Mostafavi M, Sharifi A, Mirzaei M, Amanlou M. Novel and versatile methodology for synthesis of b-aryl-bmercapto ketone derivatives as potential urease inhibitors. *J Iran Chem Soc.* 2014;11:1113–1119.
33. Fu G-Y, Zhang X-L, Sheng S-R, Wei M-H, Liu X-L. Rapid microwave-assisted liquid-phase synthesis of 4-substituted-5-methoxycarbonyl-6-methyl-3,4-dihydropyridones on poly(ethylene glycol) support. *Synth Commun.* 2008;38(8):1249-1258.
34. Ruiz E, Rodríguez H, Coro J, Salfrán E, Suárez M, Martínez-Alvarez R, et al. Ultrasound-assisted one-pot, four component synthesis of 4-aryl 3,4-dihydropyridone derivatives. *Ultrason Sonochem.* 2010;18(1):32-36.
35. Rodríguez H, Suarez M, Pérez R, Petit A, Loupy A. Solvent-free synthesis of 4-aryl substituted 5-alkoxycarbonyl-6-methyl-3,4-dihydropyridones under microwave irradiation. *Tetrahedron Lett.* 2003;44(18):3709-3712.

36. Svetlik J, Goljer I, Turecek F. Oxygen-bridged tetrahydropyridines, hexahydropyridines, and dihydropyridones via a Hantzsch-like synthesis with 4-(2-hydroxyphenyl)but-3-en-2-one. *J Chem Soc, Perkin Trans 1*. 1990;5:1315-1318.
37. Morales A, Ochoa E, Suárez M, Verdecia Y, González L, Martín N, *et al.* Novel hexahydrofuro[3,4-b]-2(1H)-pyridones from 4-aryl substituted 5-alkoxycarbonyl-6-methyl-3,4-dihydropyridones. *J Heterocycl Chem*. 1996;33(1):103-107.
38. Mohammadi Ziarani G, Mousavi S, Lashgari N, Badii A. Mesoporous SBA-15-Pr-SO<sub>3</sub>H: an efficient solid acid catalyst for one-pot and solvent-free synthesis of 3,4-dihydro-2-pyridone derivatives. *J Chem Sci*. 2013;125(6):1359-1364.